When tumor tissue from NSCLC patients harbors activating EGFR gene mutations, these can be treated with tyrosine kinase inhibitors (TKIs), such as gefitinib and afatinib (Beagan et al., 2020). This evidence concerns the gene EGFR and non-small cell lung carcinoma.